1
|
Chan AHP, Xu XS, Chin IL, Grant AJ, Lau K, Hu Y, Michael PL, Lam YT, Wise SG, Tan RP. Dapansutrile OLT1177 suppresses foreign body response inflammation while preserving vascularisation of implanted materials. J Mater Chem B 2024. [PMID: 38973614 DOI: 10.1039/d4tb00705k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/09/2024]
Abstract
Mitigating inflammation associated with the foreign body response (FBR) remains a significant challenge in enhancing the performance of implantable medical devices. Current anti-inflammatory approaches aim to suppress implant fibrosis, the major outcome of the FBR, but also inadvertently inhibit beneficial immune signalling necessary for tissue healing and vascularization. In a previous study, we demonstrated the feasibility of 'selective' immunosuppression targeting the NLRP3 inflammasome using the small molecule inhibitor MCC950, leading to reduced implant fibrosis without compromising healing and leading to enhanced vascularization. However, the clinical potential of MCC950 is severely limited due to its failure to pass Phase I clinical safety trials. This has triggered substantial efforts to develop safer analogues of NLRP3 inhibitors. Dapansutrile (OLT1177) is emerging as a leading candidate amongst current NLRP3 inhibitors, demonstrating both safety and effectiveness in a growing number of clinical indications and Phase 2 trials. While the anti-inflammatory effects of OLT1177 have been shown, validation of these effects in the context of implanted materials and the FBR have not yet been demonstrated. In this study, we show OLT1177 possesses beneficial effects on key cell types which drive FBR outcomes, including macrophages, fibroblasts, and smooth muscle cells. Evaluation of OLT1177 in a 28 day subcutaneous implantation model showed OLT1177 reduced fibrotic capsule formation while promoting implant vascularization. Mechanistic studies revealed that this occurred through activation of early pro-angiogenic markers while suppressing late-stage anti-angiogenic markers. These findings establish OLT1177 as a promising therapeutic approach for mitigating implant fibrosis while supporting vascularisation, suggesting a highly promising selective immunosuppressive strategy for the FBR warranting further research to explore its optimal integration into medical materials and devices.
Collapse
Affiliation(s)
- Alex H P Chan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Xueying S Xu
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Ian L Chin
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Angus J Grant
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Kieran Lau
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Yunfei Hu
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Praveesuda L Michael
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Yuen Ting Lam
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, NSW 2006, Australia.
| |
Collapse
|
2
|
Chan AHP, Moore MJ, Grant AJ, Lam YTM, Darnell MV, Michael PL, Wise SG, Tan RP. Selective Immunosuppression Targeting the NLRP3 Inflammasome Mitigates the Foreign Body Response to Implanted Biomaterials While Preserving Angiogenesis. Adv Healthc Mater 2023; 12:e2301571. [PMID: 37846971 DOI: 10.1002/adhm.202301571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 10/04/2023] [Indexed: 10/18/2023]
Abstract
Medical devices are a mainstay of the healthcare industry, providing clinicians with innovative tools to diagnose, monitor, and treat a range of medical conditions. For implantable devices, it is widely regarded that chronic inflammation during the foreign body response (FBR) is detrimental to device performance, but also required for tissue regeneration and host integration. Current strategies to mitigate the FBR rely on broad acting anti-inflammatory drugs, most commonly, dexamethasone (DEX), which can inhibit angiogenesis and compromise long-term device function. This study challenges prevailing assumptions by suggesting that FBR inflammation is multifaceted, and selectively targeting its individual pathways can stop implant fibrosis while preserving beneficial repair pathways linked to improved device performance. MCC950, an anti-inflammatory drug that selectively inhibits the NLRP3 inflammasome, targets pathological inflammation without compromising global immune function. The effects of MCC950 and DEX on the FBR are compared using implanted polycaprolactone (PCL) scaffolds. The results demonstrate that both DEX and MCC950 halt immune cell recruitment and cytokine release, leading to reduced FBR. However, MCC950 achieves this while supporting capillary growth and enhancing tissue angiogenesis. These findings support selective immunosuppression approaches as a potential future direction for treating the FBR and enhancing the longevity and safety of implantable devices.
Collapse
Affiliation(s)
- Alex H P Chan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Matthew J Moore
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Angus J Grant
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Yuen Ting Monica Lam
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Matthew V Darnell
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Praveesuda L Michael
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Steven G Wise
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Richard P Tan
- School of Medical Sciences, Faculty of Health and Medicine, University of Sydney, Sydney, NSW, 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia
| |
Collapse
|
3
|
Yang N, Moore MJ, Michael PL, Santos M, Lam YT, Bao S, Ng MKC, Rnjak‐Kovacina J, Tan RP, Wise SG. Silk Fibroin Scaffold Architecture Regulates Inflammatory Responses and Engraftment of Bone Marrow-Mononuclear Cells. Adv Healthc Mater 2021; 10:e2100615. [PMID: 33963682 DOI: 10.1002/adhm.202100615] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Indexed: 12/13/2022]
Abstract
Despite being one of the most clinically trialed cell therapies, bone marrow-mononuclear cell (BM-MNC) infusion has largely failed to fulfill its clinical promise. Implanting biomimetic scaffolds at sites of injury prior to BM-MNC infusion is a promising approach to enhance BM-MNC engraftment and therapeutic function. Here, it is demonstrated that scaffold architecture can be leveraged to regulate the immune responses that drive BM-MNC engraftment. Silk scaffolds with thin fibers and low porosity (LP) impairs immune activation in vitro compared with thicker fiber, high porosity (HP) scaffolds. Using the authors' established in vivo bioluminescent BM-MNC tracking model, they showed that BM-MNCs home to and engraft in greater numbers in HP scaffolds over 14 days. Histological analysis reveals thicker fibrous capsule formation, with enhanced collagen deposition in HP compared to LP scaffolds consistent with substantially more native CD68+ macrophages and CD4+ T cells, driven by their elevated pro-inflammatory M1 and Th1 phenotypes, respectively. These results suggest that implant architecture impacts local inflammation that drives differential engraftment and remodeling behavior of infused BM-MNC. These findings inform the future design of biomimetic scaffolds that may better enhance the clinical effectiveness of BM-MNC infusion therapy.
Collapse
Affiliation(s)
- Nianji Yang
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Matthew J. Moore
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Praveesuda L. Michael
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Miguel Santos
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Yuen Ting Lam
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Shisan Bao
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Martin K. C. Ng
- Sydney Medical School The University of Sydney Sydney NSW 2006 Australia
- Department of Cardiology Royal Prince Alfred Hospital Sydney NSW 2042 Australia
| | - Jelena Rnjak‐Kovacina
- Graduate School of Biomedical Engineering University of New South Wales Sydney NSW 2052 Australia
| | - Richard P. Tan
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
| | - Steven G. Wise
- School of Medical Sciences Faculty of Health and Medicine The University of Sydney Sydney NSW 2006 Australia
- Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
- The University of Sydney Nano Institute (Sydney Nano) The University of Sydney Sydney NSW 2006 Australia
| |
Collapse
|
4
|
Nanofibrous Gelatin-Based Biomaterial with Improved Biomimicry Using D-Periodic Self-Assembled Atelocollagen. Biomimetics (Basel) 2021; 6:biomimetics6010020. [PMID: 33803778 PMCID: PMC8006151 DOI: 10.3390/biomimetics6010020] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 03/12/2021] [Accepted: 03/15/2021] [Indexed: 01/14/2023] Open
Abstract
Design of bioinspired materials that mimic the extracellular matrix (ECM) at the nanoscale is a challenge in tissue engineering. While nanofibrillar gelatin materials mimic chemical composition and nano-architecture of natural ECM collagen components, it lacks the characteristic D-staggered array (D-periodicity) of 67 nm, which is an important cue in terms of cell recognition and adhesion properties. In this study, a nanofibrous gelatin matrix with improved biomimicry is achieved using a formulation including a minimal content of D-periodic self-assembled atelocollagen. We suggest a processing route approach consisting of the thermally induced phase separation of the gelatin based biopolymeric mixture precursor followed by chemical-free material cross-linking. The matrix nanostructure is characterized using field emission gun scanning electron microscopy (FEG-SEM), transmission electron microscopy (TEM), wide angle X-ray diffraction (XRD) and Fourier-transform infrared spectroscopy (FT-IR). The cell culture assays indicate that incorporation of 2.6 wt.% content of D-periodic atelocollagen to the gelatin material, produces a significant increase of MC3T3-E1 mouse preosteoblast cells attachment and human mesenchymal stem cells (hMSCs) proliferation, in comparison with related bare gelatin matrices. The presented results demonstrate the achievement of an efficient route to produce a cost-effective, compositionally defined and low immunogenic “collagen-like” instructive biomaterial, based on gelatin.
Collapse
|
5
|
Wang L, Lee DJ, Han H, Zhao L, Tsukamoto H, Kim YI, Musicant AM, Parag-Sharma K, Hu X, Tseng HC, Chi JT, Wang Z, Amelio AL, Ko CC. Application of bioluminescence resonance energy transfer-based cell tracking approach in bone tissue engineering. J Tissue Eng 2021; 12:2041731421995465. [PMID: 33643604 PMCID: PMC7894599 DOI: 10.1177/2041731421995465] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 01/28/2021] [Indexed: 02/05/2023] Open
Abstract
Bioluminescent imaging (BLI) has emerged as a popular in vivo tracking modality in bone regeneration studies stemming from its clear advantages: non-invasive, real-time, and inexpensive. We recently adopted bioluminescence resonance energy transfer (BRET) principle to improve BLI cell tracking and generated the brightest bioluminescent signal known to date, which thus enables more sensitive real-time cell tracking at deep tissue level. In the present study, we brought BRET-based cell tracking strategy into the field of bone tissue engineering for the first time. We labeled rat mesenchymal stem cells (rMSCs) with our in-house BRET-based GpNLuc reporter and evaluated the cell tracking efficacy both in vitro and in vivo. In scaffold-free spheroid 3D culture system, using BRET-based GpNLuc labeling resulted in significantly better correlation to cell numbers than a fluorescence based approach. In scaffold-based 3D culture system, GpNLuc-rMSCs displayed robust bioluminescence signals with minimal background noise. Furthermore, a tight correlation between BLI signal and cell number highlighted the robust reliability of using BRET-based BLI. In calvarial critical sized defect model, robust signal and the consistency in cell survival evaluation collectively supported BRET-based GpNLuc labeling as a reliable approach for non-invasively tracking MSC. In summary, BRET-based GpNLuc labeling is a robust, reliable, and inexpensive real-time cell tracking method, which offers a promising direction for the technological innovation of BLI and even non-invasive tracking systems, in the field of bone tissue engineering.
Collapse
Affiliation(s)
- Lufei Wang
- Division of Oral and Craniofacial Health Sciences, University of North Carolina Adams School of Dentistry, Chapel Hill, NC, USA
| | - Dong Joon Lee
- Division of Oral and Craniofacial Health Sciences, University of North Carolina Adams School of Dentistry, Chapel Hill, NC, USA
| | - Han Han
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Lixing Zhao
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Hiroshi Tsukamoto
- Research & Development Center, Nitta Gelatin Inc., Yao-City, Osaka, Japan
| | - Yong-Il Kim
- Department of Orthodontics, School of Dentistry, Pusan National University, Yangsan, South Korea
| | - Adele M Musicant
- Graduate Curriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Kshitij Parag-Sharma
- Graduate Curriculum in Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Xiangxiang Hu
- Division of Oral and Craniofacial Health Sciences, University of North Carolina Adams School of Dentistry, Chapel Hill, NC, USA
| | - Henry C Tseng
- Duke Eye Center and Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA
| | - Jen-Tsan Chi
- Department of Molecular Genetics and Microbiology, Center for Genomics and Computational Biology, Duke University Medical Center, Durham, NC, USA
| | - Zhengyan Wang
- Department of Pediatric Dentistry, University of North Carolina Adams School of Dentistry, Chapel Hill, NC, USA
| | - Antonio L Amelio
- Division of Oral and Craniofacial Health Sciences, University of North Carolina Adams School of Dentistry, Chapel Hill, NC, USA.,Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Ching-Chang Ko
- Division of Orthodontics, The Ohio State University College of Dentistry, Columbus, OH, USA
| |
Collapse
|
6
|
Tan RP, Hallahan N, Kosobrodova E, Michael PL, Wei F, Santos M, Lam YT, Chan AHP, Xiao Y, Bilek MMM, Thorn P, Wise SG. Bioactivation of Encapsulation Membranes Reduces Fibrosis and Enhances Cell Survival. ACS APPLIED MATERIALS & INTERFACES 2020; 12:56908-56923. [PMID: 33314916 DOI: 10.1021/acsami.0c20096] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Encapsulation devices are an emerging barrier technology designed to prevent the immunorejection of replacement cells in regenerative therapies for intractable diseases. However, traditional polymers used in current devices are poor substrates for cell attachment and induce fibrosis upon implantation, impacting long-term therapeutic cell viability. Bioactivation of polymer surfaces improves local host responses to materials, and here we make the first step toward demonstrating the utility of this approach to improve cell survival within encapsulation implants. Using therapeutic islet cells as an exemplar cell therapy, we show that internal surface coatings improve islet cell attachment and viability, while distinct external coatings modulate local foreign body responses. Using plasma surface functionalization (plasma immersion ion implantation (PIII)), we employ hollow fiber semiporous poly(ether sulfone) (PES) encapsulation membranes and coat the internal surfaces with the extracellular matrix protein fibronectin (FN) to enhance islet cell attachment. Separately, the external fiber surface is coated with the anti-inflammatory cytokine interleukin-4 (IL-4) to polarize local macrophages to an M2 (anti-inflammatory) phenotype, muting the fibrotic response. To demonstrate the power of our approach, bioluminescent murine islet cells were loaded into dual FN/IL-4-coated fibers and evaluated in a mouse back model for 14 days. Dual FN/IL-4 fibers showed striking reductions in immune cell accumulation and elevated levels of the M2 macrophage phenotype, consistent with the suppression of fibrotic encapsulation and enhanced angiogenesis. These changes led to markedly enhanced islet cell survival and importantly to functional integration of the implant with the host vasculature. Dual FN/IL-4 surface coatings drive multifaceted improvements in islet cell survival and function, with significant implications for improving clinical translation of therapeutic cell-containing macroencapsulation implants.
Collapse
Affiliation(s)
- Richard P Tan
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Nicole Hallahan
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Elena Kosobrodova
- Applied Plasma and Physics, A28, School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
| | - Praveesuda L Michael
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Fei Wei
- Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4000, Australia
| | - Miguel Santos
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Yuen Ting Lam
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Alex H P Chan
- Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, United States
| | - Yin Xiao
- Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4000, Australia
| | - Marcela M M Bilek
- Applied Plasma and Physics, A28, School of Physics, University of Sydney, Physics Road, Camperdown, NSW 2006, Australia
| | - Peter Thorn
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| | - Steven G Wise
- Department of Physiology, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia
- Charles Perkins Centre, University of Sydney, John Hopkins Drive, Camperdown, NSW 2006, Australia
| |
Collapse
|
7
|
Influence of Titanium Alloy Scaffolds on Enzymatic Defense against Oxidative Stress and Bone Marrow Cell Differentiation. Int J Biomater 2020; 2020:1708214. [PMID: 32802064 PMCID: PMC7411454 DOI: 10.1155/2020/1708214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Revised: 04/30/2020] [Accepted: 06/05/2020] [Indexed: 11/17/2022] Open
Abstract
Studies have been directed towards the production of new titanium alloys, aiming for the replacement of Ti-6 Aluminium-4 Vanadium (TiAlV) alloy in the future. Many mechanisms related to biocompatibility and chemical characteristics have been studied in the field of implantology, but enzymatic defenses against oxidative stress remain underexplored. Bone marrow stromal cells have been explored as source of cells, which have the potential to differentiate into osteoblasts and therefore could be used as cells-based therapy. The objective of this study was to evaluate the activity of the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) in porous scaffolds of Ti-6 Aluminium-4 Vanadium (TiAlV), Ti-35 Niobium (TiNb), and Ti-35 Niobium-7 Zirconium-5 Tantalum (TiNbZrTa) on mouse bone marrow stromal cells. Porous titanium alloy scaffolds were prepared by powder metallurgy. After 24 hours, cells plated on the scaffolds were analyzed by scanning electron microscopy (SEM). The antioxidant enzyme activity was measured 72 hours after cell plating. Quantitative real time PCR (qRT-PCR) was performed after 3, 7, and 14 days, and Runx2 (Runt-related transcription factor2) expression was evaluated. The SEM images showed the presence of interconnected pores and growth, adhesion, and cell spreading in the 3 scaffolds. Although differences were noted for SOD and CAT activity for all scaffolds analyzed, no statistical differences were observed (p > 0.05). The osteogenic gene Runx2 presented high expression levels for TiNbZrTa at day 7, compared to the control group (TiAlV day 3). At day 14, all scaffolds had more than 2-fold induction for Runx2 mRNA levels, with statistically significant differences compared to the control group. Even though we were not able to confirm statistically significant differences to justify the replacement of TiAlV regarding antioxidant enzymes, TiNbZrTa was able to induce faster bone formation at early time points, making it a good choice for biomedical and tissue bioengineering applications.
Collapse
|
8
|
Kanda P, Benavente-Babace A, Parent S, Connor M, Soucy N, Steeves A, Lu A, Cober ND, Courtman D, Variola F, Alarcon EI, Liang W, Stewart DJ, Godin M, Davis DR. Deterministic paracrine repair of injured myocardium using microfluidic-based cocooning of heart explant-derived cells. Biomaterials 2020; 247:120010. [PMID: 32259654 DOI: 10.1016/j.biomaterials.2020.120010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 03/17/2020] [Accepted: 03/26/2020] [Indexed: 02/08/2023]
Abstract
While encapsulation of cells within protective nanoporous gel cocoons increases cell retention and pro-survival integrin signaling, the influence of cocoon size and intra-capsular cell-cell interactions on therapeutic repair are unknown. Here, we employ a microfluidic platform to dissect the impact of cocoon size and intracapsular cell number on the regenerative potential of transplanted heart explant-derived cells. Deterministic increases in cocoon size boosted the proportion of multicellular aggregates within cocoons, reduced vascular clearance of transplanted cells and enhanced stimulation of endogenous repair. The latter being attributable to cell-cell stimulation of cytokine and extracellular vesicle production while also broadening of the miRNA cargo within extracellular vesicles. Thus, by tuning cocoon size and cell occupancy, the paracrine signature and retention of transplanted cells can be enhanced to promote paracrine stimulation of endogenous tissue repair.
Collapse
Affiliation(s)
- Pushpinder Kanda
- University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada
| | | | - Sandrine Parent
- University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada
| | - Michie Connor
- University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada
| | - Nicholas Soucy
- Ottawa-Carleton Institute for Biomedical Engineering, Ottawa, K1N6N5, Canada
| | - Alexander Steeves
- Department of Mechanical Engineering, University of Ottawa, K1N6N5, Canada
| | - Aizhu Lu
- University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada
| | - Nicholas David Cober
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H8M5, Canada
| | - David Courtman
- Ottawa Hospital Research Institute, Division of Regenerative Medicine, Department of Medicine, University of Ottawa, Ottawa, K1H8L6, Canada
| | - Fabio Variola
- Department of Mechanical Engineering, University of Ottawa, K1N6N5, Canada
| | - Emilio I Alarcon
- University of Ottawa Heart Institute, Division of Cardiac Surgery, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada; Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, K1H8M5, Canada
| | - Wenbin Liang
- University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H8M5, Canada
| | - Duncan J Stewart
- Ottawa Hospital Research Institute, Division of Regenerative Medicine, Department of Medicine, University of Ottawa, Ottawa, K1H8L6, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H8M5, Canada
| | - Michel Godin
- Department of Physics, University of Ottawa, K1N6N5, Canada; Ottawa-Carleton Institute for Biomedical Engineering, Ottawa, K1N6N5, Canada; Department of Mechanical Engineering, University of Ottawa, K1N6N5, Canada
| | - Darryl R Davis
- University of Ottawa Heart Institute, Division of Cardiology, Department of Medicine, University of Ottawa, Ottawa, K1Y4W7, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, K1H8M5, Canada.
| |
Collapse
|
9
|
Yang N, Tan RP, Chan AHP, Lee BSL, Santos M, Hung J, Liao Y, Bilek MMM, Fei J, Wise SG, Bao S. Immobilized Macrophage Colony-Stimulating Factor (M-CSF) Regulates the Foreign Body Response to Implanted Materials. ACS Biomater Sci Eng 2020; 6:995-1007. [PMID: 33464851 DOI: 10.1021/acsbiomaterials.9b01887] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The functionality and durability of implanted biomaterials are often compromised by an exaggerated foreign body reaction (FBR). M1/M2 polarization of macrophages is a critical regulator of scaffold-induced FBR. Macrophage colony-stimulating factor (M-CSF), a hematopoietic growth factor, induces macrophages into an M2-like polarized state, leading to immunoregulation and promoting tissue repair. In the present study, we explored the immunomodulatory effects of surface bound M-CSF on poly-l-lactic acid (PLLA)-induced FBR. M-CSF was immobilized on the surface of PLLA via plasma immersion ion implantation (PIII). M-CSF functionalized PLLA, PLLA-only, and PLLA+PIII were assessed in an IL-1β luciferase reporter mouse to detect real-time levels of IL-1β expression, reflecting acute inflammation in vivo. Additionally, these different treated scaffolds were implanted subcutaneously into wild-type mice to explore the effect of M-CSF in polarization of M2-like macrophages (CD68+/CD206+), related cytokines (pro-inflammatory: IL-1β, TNF and MCP-1; anti-inflammatory: IL-10 and TGF-β), and angiogenesis (CD31) by immunofluorescent staining. Our data demonstrated that IL-1β activity in M-CSF functionalized scaffolds was ∼50% reduced compared to PLLA-only at day 1 (p < 0.01) and day 2 (p < 0.05) post-implantation. There were >2.6-fold more CD206+ macrophages in M-CSF functionalized PLLA compared to PLLA-only at day 7 (p < 0.001), along with higher levels of IL-10 at both day 7 (p < 0.05) and day 14 (p < 0.01), and TGF-β at day 3 (p < 0.05), day 7 (p < 0.05), and day 14 (p < 0.001). Lower levels of pro-inflammatory cytokines were also detected in M-CSF functionalized PLLA in the early phase of the immune response compared to PLLA-only: a ∼58% decrease at day 3 in IL-1β; a ∼91% decrease at day 3 and a ∼66% decrease at day 7 in TNF; and a ∼60% decrease at day 7 in MCP-1. Moreover, enhanced angiogenesis inside and on/near the scaffold was observed in M-CSF functionalized PLLA compared to PLLA-only at day 3 (p < 0.05) and day 7 (p < 0.05), respectively. Overall, M-CSF functionalized PLLA enhanced CD206+ macrophage polarization and angiogenesis, consistent with lower levels of pro-inflammatory cytokines and higher levels of anti-inflammatory cytokines in early stages of the host response, indicating potential immunoregulatory functions on the local environment.
Collapse
Affiliation(s)
- Nianji Yang
- Discipline of Pathology, University of Sydney, Sydney, New South Wales 2006, Australia.,Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Richard P Tan
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | | | - Bob S L Lee
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Miguel Santos
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Juichien Hung
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Yun Liao
- Department of Pharmacy, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Marcela M M Bilek
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia.,School of Physics, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Jian Fei
- School of Life Science and Technology, Shanghai Tongji University, Shanghai, China.,Research Centre for Model Organism, Shanghai, China
| | - Steven G Wise
- Discipline of Physiology, University of Sydney, Sydney, New South Wales 2006, Australia.,The Heart Research Institute, Sydney, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Shisan Bao
- Discipline of Pathology, University of Sydney, Sydney, New South Wales 2006, Australia.,Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
10
|
Crowley C, Butler CR, Camilli C, Hynds RE, Kolluri KK, Janes SM, De Coppi P, Urbani L. Non-Invasive Longitudinal Bioluminescence Imaging of Human Mesoangioblasts in Bioengineered Esophagi. Tissue Eng Part C Methods 2020; 25:103-113. [PMID: 30648471 PMCID: PMC6389770 DOI: 10.1089/ten.tec.2018.0351] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Esophageal engineering aims to create replacement solutions by generating hollow organs using a combination of cells, scaffolds, and regeneration-stimulating factors. Currently, the fate of cells on tissue-engineered grafts is generally determined retrospectively by histological analyses. Unfortunately, quality-controlled cell seeding protocols for application in human patients are not standard practice. As such, the field requires simple, fast, and reliable techniques for non-invasive, highly specific cell tracking. Here, we show that bioluminescence imaging (BLI) is a suitable method to track human mesoangioblast seeding of an esophageal tubular construct at every stage of the preclinical bioengineering pipeline. In particular, validation of BLI as longitudinal quantitative assessment of cell density, proliferation, seeding efficiency, bioreactor culture, and cell survival upon implantation in vivo was performed against standard methods in 2D cultures and in 3D decellularized esophageal scaffolds. The technique is simple, non-invasive, and provides information on mesoangioblast distribution over entire scaffolds. Bioluminescence is an invaluable tool in the development of complex bioartificial organs and can assist in the development of standardized cell seeding protocols, with the ability to track cells from bioreactor through to implantation.
Collapse
Affiliation(s)
- Claire Crowley
- 1 Stem Cells and Regenerative Medicine Section, UCL Institute of Child Health and Great Ormond Street Children's Hospital, University College London, London, United Kingdom
| | - Colin R Butler
- 1 Stem Cells and Regenerative Medicine Section, UCL Institute of Child Health and Great Ormond Street Children's Hospital, University College London, London, United Kingdom.,2 Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom
| | - Carlotta Camilli
- 1 Stem Cells and Regenerative Medicine Section, UCL Institute of Child Health and Great Ormond Street Children's Hospital, University College London, London, United Kingdom
| | - Robert E Hynds
- 2 Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom
| | - Krishna K Kolluri
- 2 Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom
| | - Sam M Janes
- 2 Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom
| | - Paolo De Coppi
- 1 Stem Cells and Regenerative Medicine Section, UCL Institute of Child Health and Great Ormond Street Children's Hospital, University College London, London, United Kingdom
| | - Luca Urbani
- 1 Stem Cells and Regenerative Medicine Section, UCL Institute of Child Health and Great Ormond Street Children's Hospital, University College London, London, United Kingdom.,3 Institute of Hepatology London, Foundation for Liver Research, London, United Kingdom
| |
Collapse
|
11
|
Davis CR, Than PA, Khong SML, Rodrigues M, Findlay MW, Navarrete DJ, Ghali S, Vaidya JS, Gurtner GC. Therapeutic Breast Reconstruction Using Gene Therapy-Delivered IFNγ Immunotherapy. Mol Cancer Ther 2019; 19:697-705. [PMID: 31658961 DOI: 10.1158/1535-7163.mct-19-0315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Revised: 07/26/2019] [Accepted: 10/21/2019] [Indexed: 11/16/2022]
Abstract
After mastectomy, breast reconstruction is increasingly performed using autologous tissue with the aim of improving quality of life. During this procedure, autologous tissue is excised, relocated, and reattached using microvascular anastomoses at the site of the extirpated breast. The period during which the tissue is ex vivo may allow genetic modification without any systemic exposure to the vector. Could such access permit delivery of therapeutic agents using the tissue flap as a vehicle? Such delivery may be more targeted and oncologically efficient than systemic therapy, and avoid systemic complications. The cytokine IFNγ has antitumor effects, and systemic toxicity could be circumvented by localized delivery of the IFNγ gene via gene therapy to autologous tissue used for breast reconstruction, which then releases IFNγ and exerts antitumor effects. In a rat model of loco-regional recurrence (LRR) with MADB-106-Luc and MAD-MB-231-Luc breast cancer cells, autologous tissue was transduced ex vivo with an adeno-associated viral vector encoding IFNγ. The "Therapeutic Reconstruction" released IFNγ at the LRR site and eliminated cancer cells, significantly decreased tumor burden, and increased survival compared with sham reconstruction (P <0.05). Mechanistically, localized IFNγ immunotherapy stimulated M1 macrophages to target cancer cells within the regional confines of the modified tumor environment. This concept of "Therapeutic Breast Reconstruction" using ex vivo gene therapy of autologous tissue offers a new application for immunotherapy in breast cancer with a dual therapeutic effect of both reconstructing the ablative defect and delivering local adjuvant immunotherapy.
Collapse
Affiliation(s)
- Christopher R Davis
- Stanford University School of Medicine, Stanford University, Stanford, California. .,Division of Surgery and Interventional Science, University College London, London, United Kingdom
| | - Peter A Than
- Stanford University School of Medicine, Stanford University, Stanford, California
| | - Sacha M L Khong
- Stanford University School of Medicine, Stanford University, Stanford, California
| | - Melanie Rodrigues
- Stanford University School of Medicine, Stanford University, Stanford, California
| | - Michael W Findlay
- Stanford University School of Medicine, Stanford University, Stanford, California.,The Peter MacCallum Cancer Centre, Department of Surgery, The University of Melbourne, Melbourne, Australia
| | - Daniel J Navarrete
- Stanford University School of Medicine, Stanford University, Stanford, California.,Department of Microbiology and Immunology, Stanford University, Stanford, California
| | - Shadi Ghali
- Division of Surgery and Interventional Science, University College London, London, United Kingdom
| | - Jayant S Vaidya
- Division of Surgery and Interventional Science, University College London, London, United Kingdom
| | - Geoffrey C Gurtner
- Stanford University School of Medicine, Stanford University, Stanford, California.
| |
Collapse
|
12
|
Tan RP, Chan AH, Wei S, Santos M, Lee BS, Filipe EC, Akhavan B, Bilek MM, Ng MK, Xiao Y, Wise SG. Bioactive Materials Facilitating Targeted Local Modulation of Inflammation. JACC Basic Transl Sci 2019; 4:56-71. [PMID: 30847420 PMCID: PMC6390730 DOI: 10.1016/j.jacbts.2018.10.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 10/10/2018] [Accepted: 10/12/2018] [Indexed: 11/02/2022]
Abstract
Cardiovascular disease is an inflammatory disorder that may benefit from appropriate modulation of inflammation. Systemic treatments lower cardiac events but have serious adverse effects. Localized modulation of inflammation in current standard treatments such as bypass grafting may more effectively treat CAD. The present study investigated a bioactive vascular graft coated with the macrophage polarizing cytokine interleukin-4. These grafts repolarize macrophages to anti-inflammatory phenotypes, leading to modulation of the pro-inflammatory microenvironment and ultimately to a reduction of foreign body encapsulation and inhibition of neointimal hyperplasia development. These resulting functional improvements have significant implications for the next generation of synthetic vascular grafts.
Collapse
Affiliation(s)
- Richard P. Tan
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Alex H.P. Chan
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Simon Wei
- Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Miguel Santos
- Heart Research Institute, Sydney, New South Wales, Australia
- School of Physics, University of Sydney, Sydney, New South Wales, Australia
| | - Bob S.L. Lee
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Elysse C. Filipe
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Garvan Institute of Medical Research, Cancer Division, Sydney, New South Wales, Australia
| | - Behnam Akhavan
- Heart Research Institute, Sydney, New South Wales, Australia
- School of Physics, University of Sydney, Sydney, New South Wales, Australia
- School of Aerospace, Mechanical and Mechatronic Engineering, University of Sydney, Sydney, New South Wales, Australia
| | - Marcela M. Bilek
- School of Physics, University of Sydney, Sydney, New South Wales, Australia
- School of Aerospace, Mechanical and Mechatronic Engineering, University of Sydney, Sydney, New South Wales, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia
- Sydney Nano Institute, University of Sydney, Sydney, New South Wales, Australia
| | - Martin K.C. Ng
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Yin Xiao
- Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Steven G. Wise
- Heart Research Institute, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
13
|
Tan RP, Chan AHP, Lennartsson K, Miravet MM, Lee BSL, Rnjak-Kovacina J, Clayton ZE, Cooke JP, Ng MKC, Patel S, Wise SG. Integration of induced pluripotent stem cell-derived endothelial cells with polycaprolactone/gelatin-based electrospun scaffolds for enhanced therapeutic angiogenesis. Stem Cell Res Ther 2018; 9:70. [PMID: 29562916 PMCID: PMC5863387 DOI: 10.1186/s13287-018-0824-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 02/19/2018] [Accepted: 03/05/2018] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Induced pluripotent stem-cell derived endothelial cells (iPSC-ECs) can be generated from any somatic cell and their iPSC sources possess unlimited self-renewal. Previous demonstration of their proangiogenic activity makes them a promising cell type for treatment of ischemic injury. As with many other stem cell approaches, the low rate of in-vivo survival has been a major limitation to the efficacy of iPSC-ECs to date. In this study, we aimed to increase the in-vivo lifetime of iPSC-ECs by culturing them on electrospun polycaprolactone (PCL)/gelatin scaffolds, before quantifying the subsequent impact on their proangiogenic function. METHODS iPSC-ECs were isolated and stably transfected with a luciferase reporter to facilitate quantification of cell numbers and non-invasive imaging in-vivo PCL/gelatin scaffolds were engineered using electrospinning to obtain woven meshes of nanofibers. iPSC-ECs were cultured on scaffolds for 7 days. Subsequently, cell growth and function were assessed in vitro followed by implantation in a mouseback subcutaneous model for 7 days. RESULTS Using a matrix of conditions, we found that scaffold blends with ratios of PCL:gelatin of 70:30 (PG73) spun at high flow rates supported the greatest levels of iPSC-EC growth, retention of phenotype, and function in vitro. Implanting iPSC-ECs seeded on PG73 scaffolds in vivo improved their survival up to 3 days, compared to cells directly injected into control wounds, which were no longer observable within 1 h. Enhanced engraftment improved blood perfusion, observed through non-invasive laser Doppler imaging. Immunohistochemistry revealed a corresponding increase in host angiogenic mechanisms characterized by the enhanced recruitment of macrophages and the elevated expression of proangiogenic cytokines vascular endothelial growth factor and placental growth factor. CONCLUSIONS Knowledge of these mechanisms combined with a deeper understanding of the scaffold parameters influencing this function provides the groundwork for optimizing future iPSC-EC therapies utilizing engraftment platforms. The development of combined scaffold and iPSC-EC therapies could ultimately improve therapeutic angiogenesis and the treatment of ischemic injury.
Collapse
Affiliation(s)
- Richard P Tan
- The Heart Research Institute, Sydney, NSW, 2042, Australia. .,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
| | - Alex H P Chan
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | | | | | - Bob S L Lee
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| | - Jelena Rnjak-Kovacina
- Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Zoe E Clayton
- The Heart Research Institute, Sydney, NSW, 2042, Australia
| | - John P Cooke
- Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - Martin K C Ng
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Royal Prince Alfred Hospital, Sydney, NSW, 2042, Australia
| | - Sanjay Patel
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Royal Prince Alfred Hospital, Sydney, NSW, 2042, Australia
| | - Steven G Wise
- The Heart Research Institute, Sydney, NSW, 2042, Australia.,Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia
| |
Collapse
|
14
|
Abstract
Angiogenesis plays an important role not only in the growth and regeneration of tissues in humans but also in pathological conditions such as inflammation, degenerative disease and the formation of tumors. Angiogenesis is also vital in thick engineered tissues and constructs, such as those for the heart and bone, as these can face difficulties in successful implantation if they are insufficiently vascularized or unable to connect to the host vasculature. Considerable research has been carried out on angiogenic processes using a variety of approaches. Pathological angiogenesis has been analyzed at the cellular level through investigation of cell migration and interactions, modeling tissue level interactions between engineered blood vessels and whole organs, and elucidating signaling pathways involved in different angiogenic stimuli. Approaches to regenerative angiogenesis in ischemic tissues or wound repair focus on the vascularization of tissues, which can be broadly classified into two categories: scaffolds to direct and facilitate tissue growth and targeted delivery of genes, cells, growth factors or drugs that promote the regeneration. With technological advancement, models have been designed and fabricated to recapitulate the innate microenvironment. Moreover, engineered constructs provide not only a scaffold for tissue ingrowth but a reservoir of agents that can be controllably released for therapeutic purposes. This review summarizes the current approaches for modeling pathological and regenerative angiogenesis in the context of micro-/nanotechnology and seeks to bridge these two seemingly distant aspects of angiogenesis. The ultimate aim is to provide insights and advances from various models in the realm of angiogenesis studies that can be applied to clinical situations.
Collapse
Affiliation(s)
- Li-Jiun Chen
- Department of Finemechanics, Graduate School of Engineering, Tohoku University, 6-6-01 Aramaki, Aoba-ku, Sendai 980-8579, Japan.
| | | |
Collapse
|
15
|
|
16
|
Jiang Z, Wang H, Yu K, Feng Y, Wang Y, Huang T, Lai K, Xi Y, Yang G. Light-Controlled BMSC Sheet-Implant Complexes with Improved Osteogenesis via an LRP5/β-Catenin/Runx2 Regulatory Loop. ACS APPLIED MATERIALS & INTERFACES 2017; 9:34674-34686. [PMID: 28879758 DOI: 10.1021/acsami.7b10184] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The combination of bone marrow mesenchymal stem cell (BMSC) sheets and titanium implants (BMSC sheet-implant complexes) can accelerate osseointegration. However, methods of fabricating BMSC sheet-implant complexes are quite limited, and the survival of BMSC sheet-implant complexes is one of the key barriers. Here, we show that a light-controlled fabricating system can generate less injured BMSC sheet-implant complexes with improved viability and osteogenesis and that noninvasive monitoring of the viability of BMSC sheet-implant complexes using a lentiviral delivery system is feasible. Enhanced green fluorescent protein- and luciferase-expressing BMSC sheets were used to track the viability of BMSC sheet-implant complexes in vivo. The experiments of micro-computed tomography analysis and hard tissue slices were performed to evaluate the osteogenic ability of BMSC sheet-implant complexes in vivo. The results showed that BMSC sheet-implant complexes survived for almost 1 month after implantation. Notably, BMSC sheet-implant complexes fabricated by the light-controlled fabricating system had upregulating expression levels of low-density lipoprotein-receptor-related protein 5 (LRP5), β-catenin, and runt-related transcription factor 2 (Runx2) compared to the complexes fabricated by mechanical scraping. Furthermore, we found that Runx2 directly bound to the rat LRP5 promoter and the LRP5/β-catenin/Runx2 regulatory loop contributed to the enhancement of the osseointegrating potentials. In this study, we successfully fabricated BMSC sheet-implant complexes with improved viability and osteogenesis and established a feasible, noninvasive, and continuous method for tracking BMSC sheet-implant complexes in vivo. Our findings lay the foundation for the application of BMSC sheet-implant complexes in vivo and open new avenues for engineered BMSC sheet-implant complexes.
Collapse
Affiliation(s)
- Zhiwei Jiang
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Huiming Wang
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Ke Yu
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Yuting Feng
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Ying Wang
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Tingben Huang
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Kaichen Lai
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Yue Xi
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| | - Guoli Yang
- Department of Implantology, Stomatology Hospital, School of Medicine, ‡Department of Oral and Maxillofacial Surgery, Stomatology Hospital, School of Medicine, and §Department of Oral Medicine, Stomatology Hospital, School of Medicine, Zhejiang University , Yan'an Road, Hangzhou 310058, P. R. China
| |
Collapse
|